Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07077213 · ClinicalTrials.gov registry record
18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients
A clinical trial, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- 30
- Enrollment target
NCT07077213: Recruiting study, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT07077213 is a clinical trial that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07077213 is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
Study Summary
The investigators will assess the hypothesis is that 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) Positron emission tomography (PET) could be used as a noninvasive biomarker to assess post-tuberculosis (post-TB) lung disease and fibrosis in TB patients. Microbiologically confirmed patients with active tuberculosis will be invited to participate in the study. A whole-body PET scan will be performed after 18F-FAPI-74 intravenous injection and correlation will be made with sites of TB lesions noted on CT. It is anticipated that 18F-FAPI-74 PET will be able to detect fibrosis (with high sensitivity) in the TB lesions.
Primary Outcome
Characterization of lesional fibrosis using 18F-FAPI-74 PET/CT in tuberculosis patients. Whole-body PET/CT scans will be obtained after intravenous injection of 18F-FAPI-74. Uptake will be measured at sites of TB lesions and unaffected areas.
Interventions
- COMBINATION_PRODUCT 18F-FAPI-74
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-03-12 |
| Est. Completion | 2027-12-01 |
What NCT07077213 shows while recruiting
NCT07077213 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which 18F-FAPI-74 is the first listed.
NCT07077213 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07077213 about?
NCT07077213 is a clinical study titled "18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients". The investigators will assess the hypothesis is that 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) Positron emission tomography (PET) could be used as a noninvasive biomarker to assess post-tuberculosis (post-TB) lung disease and fibrosis in TB patients. Microbiologically confirmed pati...
What is the current status of trial NCT07077213?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2026-03-12. Estimated completion is 2027-12-01.
What interventions are being tested in trial NCT07077213?
The interventions under investigation include: 18F-FAPI-74 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07077213?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI